Ionis Pharmaceuticals, Inc. (IONS): Price and Financial Metrics

Ionis Pharmaceuticals, Inc. (IONS)

Today's Latest Price: $56.21 USD

0.30 (-0.53%)

Updated Aug 7 12:00am

Add IONS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

IONS Stock Summary

  • IONS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 672.98 -- higher than 94.39% of US-listed equities with positive expected earnings growth.
  • The price/operating cash flow metric for Ionis Pharmaceuticals Inc is higher than 89.38% of stocks in our set with a positive cash flow.
  • The volatility of Ionis Pharmaceuticals Inc's share price is greater than that of just 5.18% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to IONS, based on their financial statements, market capitalization, and price volatility, are ACRS, SWKS, RESN, TBPH, and ACIA.
  • Visit IONS's SEC page to see the company's official filings. To visit the company's web site, go to
IONS Daily Price Range
IONS 52-Week Price Range

IONS Stock Price Chart Technical Analysis Charts

IONS Price/Volume Stats

Current price $56.21 52-week high $73.09
Prev. close $56.51 52-week low $39.32
Day low $55.22 Volume 1,217,100
Day high $56.75 Avg. volume 892,920
50-day MA $59.18 Dividend yield N/A
200-day MA $57.28 Market Cap 7.85B

Ionis Pharmaceuticals, Inc. (IONS) Company Bio

Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

IONS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$56.21$28.62 -50%

We started the process of determining a valid price forecast for Ionis Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Ionis Pharmaceuticals Inc ranked in the 31th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 50%. As for the metrics that stood out in our discounted cash flow analysis of Ionis Pharmaceuticals Inc, consider:

  • The company has produced more trailing twelve month cash flow than 56.72% of its sector Healthcare.
  • 91% of the company's capital comes from equity, which is greater than 78.42% of stocks in our cash flow based forecasting set.
  • The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than merely 21.54% of the free cash flow producing stocks we're observing.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Ionis Pharmaceuticals Inc? See PDEX, ZTS, ESMC, PRAH, and XRAY.

IONS Latest News Stream

Event/Time News Detail
Loading, please wait...

IONS Latest Social Stream

Loading social stream, please wait...

View Full IONS Social Stream

Latest IONS News From Around the Web

Below are the latest news stories about Ionis Pharmaceuticals Inc that investors may wish to consider to help them evaluate IONS as an investment opportunity.

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 29, 2020

Ionis Pharmaceuticals to hold second quarter 2020 financial results webcast

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, August 5th at 11:30 a.m. Eastern Time…

PR Newswire | July 22, 2020

Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast

Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, August 4 at 4:30 p.m. Eastern Time to discuss its second quarter 2020 financial results and report on pipeline and business progress.

Yahoo | July 21, 2020

Akcea Appoints New Senior Vice President, Global Medical Affairs

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Christophe Hotermans, M.D., Ph.D., has joined the company as senior vice president of global medical affairs where he will lead and evolve the execution of medical strategies, activities and operations worldwide in collaboration with executive management.

Yahoo | July 20, 2020

Did Hedge Funds Make The Right Call On Ionis Pharmaceuticals, Inc. (IONS) ?

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]

Yahoo | July 17, 2020

Read More 'IONS' Stories Here

IONS Price Returns

1-mo -9.47%
3-mo 0.05%
6-mo -6.80%
1-year -17.87%
3-year 23.38%
5-year 11.28%
YTD -6.95%
2019 11.75%
2018 7.48%
2017 5.16%
2016 -22.77%
2015 0.31%

Continue Researching IONS

Want to see what other sources are saying about Ionis Pharmaceuticals Inc's financials and stock price? Try the links below:

Ionis Pharmaceuticals Inc (IONS) Stock Price | Nasdaq
Ionis Pharmaceuticals Inc (IONS) Stock Quote, History and News - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8557 seconds.